Capricor Therapeutics Inc (CAPR)
9.95
-0.04
(-0.40%)
USD |
NASDAQ |
Sep 27, 16:00
10.01
+0.06
(+0.60%)
After-Hours: 20:00
Capricor Therapeutics Enterprise Value: 294.30M for Sept. 27, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 27, 2024 | 294.30M |
| September 26, 2024 | 295.60M |
| September 25, 2024 | 306.99M |
| September 24, 2024 | 266.64M |
| September 23, 2024 | 164.80M |
| September 20, 2024 | 134.86M |
| September 19, 2024 | 132.91M |
| September 18, 2024 | 137.14M |
| September 17, 2024 | 135.84M |
| September 16, 2024 | 114.03M |
| September 13, 2024 | 119.89M |
| September 12, 2024 | 106.55M |
| September 11, 2024 | 106.55M |
| September 10, 2024 | 109.80M |
| September 09, 2024 | 107.20M |
| September 06, 2024 | 103.30M |
| September 05, 2024 | 108.50M |
| September 04, 2024 | 112.08M |
| September 03, 2024 | 112.73M |
| August 30, 2024 | 119.24M |
| August 29, 2024 | 123.47M |
| August 28, 2024 | 123.15M |
| August 27, 2024 | 126.24M |
| August 26, 2024 | 129.65M |
| August 23, 2024 | 118.92M |
| Date | Value |
|---|---|
| August 22, 2024 | 119.57M |
| August 21, 2024 | 119.57M |
| August 20, 2024 | 103.62M |
| August 19, 2024 | 102.65M |
| August 16, 2024 | 99.39M |
| August 15, 2024 | 97.44M |
| August 14, 2024 | 94.84M |
| August 13, 2024 | 98.25M |
| August 12, 2024 | 98.09M |
| August 09, 2024 | 92.88M |
| August 08, 2024 | 96.79M |
| August 07, 2024 | 86.38M |
| August 06, 2024 | 95.60M |
| August 05, 2024 | 91.12M |
| August 02, 2024 | 94.96M |
| August 01, 2024 | 95.60M |
| July 31, 2024 | 100.39M |
| July 30, 2024 | 101.03M |
| July 29, 2024 | 106.47M |
| July 26, 2024 | 110.31M |
| July 25, 2024 | 112.23M |
| July 24, 2024 | 116.06M |
| July 23, 2024 | 123.42M |
| July 22, 2024 | 124.06M |
| July 19, 2024 | 120.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-4.972M
Minimum
Mar 10 2020
306.99M
Maximum
Sep 25 2024
67.28M
Average
63.58M
Median
Feb 03 2023
Enterprise Value Benchmarks
| ResMed Inc | 35.59B |
| AIM ImmunoTech Inc | 8.574M |
| Perspective Therapeutics Inc | 556.40M |
| Protalix BioTherapeutics Inc | 52.61M |
| Armata Pharmaceuticals Inc | 170.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.00M |
| Revenue (Quarterly) | 3.971M |
| Total Expenses (Quarterly) | 15.56M |
| EPS Diluted (Quarterly) | -0.35 |
| Profit Margin (Quarterly) | -277.0% |
| Earnings Yield | -8.94% |
| Normalized Earnings Yield | -9.615 |